Specialized Trials HRI runs HAL/HAP, psychedelic studies, driving simulations, and first-in-human pharmacology, supported by capabilities in neuroimaging, electrophysiology, pain models, and drug compounding. This unique mix positions HRI to win early-phase and complex trials where data depth and specialized endpoints matter.

Strategic Partnership As a division of Apex Innovative Sciences, HRI benefits from an integrated CRO ecosystem, merger history with CNS and Clinical Trial Centers Alliance, and backing from investors. This enables cross-site enrollment opportunities, shared services, and streamlined sponsor onboarding for multi-site studies.

Inpatient Capacity With 88 inpatient beds across Marlton and Berlin and robust outpatient capabilities, HRI can support studies requiring hospitalization, intense monitoring, or long-term follow-up. This capacity can improve enrollment velocity and protocol adherence for high-complexity trials.

Diverse Cohorts HRI conducts studies across many patient populations and healthy subjects, enabling diverse recruitment strategies for broad endpoints. The ability to enroll specialized cohorts (including psychedelic research) expands sponsor access to rare or hard-to-recruit populations.

Leadership Credibility Founded by investigators with decades of experience, HRI brings credibility and rigorous clinical governance. The combination of HIPAA compliant operations and a modern tech stack underpins reliable data handling, audit readiness, and sponsor confidence.